Anika Therapeutics, Inc. Income Statement
ANIK|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Anika Therapeutics, Inc. reported $113M in revenue and $11M in net loss for FY2025. Revenue has grown at a 7.7% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $130.5M | $114.6M | $105.6M | $113.4M | $103.4M | $93.0M | $105.6M | $75.1M | $71.4M | $64.8M | $55.6M | $40.1M |
| Cost of Revenue | $49.0M | $43.9M | $38.3M | $61.4M | $28.7M | $31.3M | $27.4M | $24.0M | $21.1M | $20.9M | $22.8M | $29.0M | $26.8M | $23.8M | $13.7M |
| Gross Profit | $63.8M | $76.0M | $82.5M | $69.0M | $85.9M | $74.3M | $17.4M | $13.4M | $17.3M | $16.9M | $11.2M | $10.0M | $9.7M | $7.2M | - |
| SG&A Expense | $49.1M | $55.6M | $59.9M | $60.1M | $35.0M | $34.3M | $21.5M | $18.0M | $14.8M | $15.1M | $12.9M | $14.7M | $17.9M | $17.3M | $10.5M |
| R&D Expense | $25.8M | $25.5M | $21.8M | $23.4M | $16.7M | $18.2M | $18.8M | $10.7M | $9.0M | $8.1M | $7.1M | $5.4M | $6.2M | $6.9M | $8.2M |
| Operating Income | -$11.1M | -$5.1M | $844.0K | -$28.3M | $34.2M | $21.7M | $45.7M | $50.6M | $48.1M | $61.4M | $32.6M | $19.7M | $14.0M | $7.5M | $5.6M |
| Income Tax | $672.0K | $6.1M | $6.6M | -$4.6M | $8.9M | $4.5M | $14.4M | $18.3M | $17.5M | $23.2M | $11.9M | $7.8M | $5.3M | $3.0M | $1.8M |
| Net Income | -$10.9M | -$56.4M | -$82.7M | -$24.0M | $27.2M | $18.7M | $31.8M | $32.5M | $30.8M | $38.3M | $20.6M | $11.8M | $8.5M | $4.3M | $3.7M |
| EPS (Basic) | -$5.64 | -$1.02 | $0.29 | -$1.69 | $1.93 | $1.30 | $2.18 | $2.22 | $2.06 | $2.61 | $1.46 | $0.89 | $0.65 | $0.34 | $0.32 |
| EPS (Diluted) | -$5.64 | -$1.02 | $0.28 | -$1.69 | $1.89 | $1.27 | $2.11 | $2.15 | $2.01 | $2.51 | $1.39 | $0.82 | $0.62 | $0.32 | $0.32 |
| Shares Outstanding | 14.4M | 14.7M | 14.6M | 14.4M | 14.3M | 14.3M | 14.2M | 14.7M | 14.6M | 15.0M | 14.9M | 14.3M | 13.9M | 13.6M | 13.5M |
| Gross Margin | 56.6% | 63.4% | 68.3% | 52.9% | 74.9% | 70.4% | 15.3% | 13.0% | 18.6% | 16.0% | 14.9% | 14.0% | 14.9% | 13.0% | - |
| Operating Margin | -9.8% | -4.3% | 0.7% | -21.7% | 29.9% | 20.6% | 40.3% | 48.9% | 51.8% | 58.2% | 43.4% | 27.6% | 21.6% | 13.6% | 13.9% |
| Profit Margin | -9.6% | -47.0% | -68.4% | -18.4% | 23.7% | 17.7% | 28.1% | 31.5% | 33.1% | 36.3% | 27.4% | 16.5% | 13.1% | 7.8% | 9.2% |